Vizora日本語

Wakamoto PharmaceuticalWAKAMOTO PHARMACEUTICAL CO.,LTD.4512東証スタンダード医薬品FY ending Mar 2026, non-consolidated, J-GAAP

Wakamoto Pharmaceutical FY ending Mar 2026 results

About 48% of Wakamoto Pharmaceutical's sales come from Ethical products business-related, with Otc products business-Related and Global Sales Development business-Related making up much of the rest.

Out of every ¥100 of sales, about ¥3 is left as operating profit.

Revenue changed +27.2% from the prior year, and it swung back to an operating profit.

Revenue and profit pattern

Turned profitable

What changed from last year

FY ending Mar 2025 → FY ending Mar 2026

Revenue
+27.2%¥7.79B → ¥9.91B
Gross profit
+30.6%¥3.62B → ¥4.73B
Operating income
Back to profit-¥457.8M → ¥255.5M
Operating cash flow
Loss-¥592.5M → -¥486.9M
Free cash flow
Loss-¥1.07B → -¥1.1B

Where the money goes

FY ending Mar 2025 → FY ending Mar 2026

Where ¥100 of sales goes

For every ¥100 Wakamoto Pharmaceutical sells, how much goes where, and how much is kept.

FY ending Mar 2026
Cost of sales
¥52
SG&A
¥45
Operating profit
¥3
Net profit kept
¥2

Annual margin trends

Gross margin47.7%
FY ending Mar 2021: 50.5%50.5%FY ending Mar 2022: 52.0%52.0%FY ending Mar 2023: 47.4%47.4%FY ending Mar 2024: 46.5%46.5%FY ending Mar 2025: 46.5%46.5%FY ending Mar 2026: 47.7%47.7%FY21FY22FY23FY24FY25FY26
Operating margin2.6%
FY ending Mar 2021: -8.5%-8.5%FY ending Mar 2022: -0.2%-0.2%FY ending Mar 2023: 1.6%1.6%FY ending Mar 2024: -2.5%-2.5%FY ending Mar 2025: -5.9%-5.9%FY ending Mar 2026: 2.6%2.6%FY21FY22FY23FY24FY25FY26
Net margin2.3%
FY ending Mar 2021: -6.8%-6.8%FY ending Mar 2022: 2.8%2.8%FY ending Mar 2023: 1.6%1.6%FY ending Mar 2024: 1.4%1.4%FY ending Mar 2025: 0.8%0.8%FY ending Mar 2026: 2.3%2.3%FY21FY22FY23FY24FY25FY26

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2026

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (6)

  • EDINET (FSA Japan)

    有価証券報告書－第131期(2025/04/01－2026/03/31)

    ID S100YDBU2026-06-18Open

  • EDINET (FSA Japan)

    有価証券報告書－第130期(2024/04/01－2025/03/31)

    ID S100W0QM2025-06-20Open

  • EDINET (FSA Japan)

    有価証券報告書－第129期(2023/04/01－2024/03/31)

    ID S100TTRJ2024-06-28Open

  • EDINET (FSA Japan)

    有価証券報告書－第128期(2022/04/01－2023/03/31)

    ID S100R6G72023-06-28Open

  • EDINET (FSA Japan)

    有価証券報告書－第127期(令和3年4月1日－令和4年3月31日)

    ID S100OCE22022-06-24Open

  • EDINET (FSA Japan)

    有価証券報告書－第126期(令和2年4月1日－令和3年3月31日)

    ID S100LMJG2021-06-25Open

Extracted from XBRL: 47 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image